SiBone $SIBN Stake Trimmed by Brown Advisory Inc.

Brown Advisory Inc. lowered its stake in SiBone (NASDAQ:SIBN) by 11.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,461,802 shares of the company’s stock after selling 311,365 shares during the quarter. Brown Advisory Inc. owned approximately 0.06% of SiBone worth $48,547,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. ANTIPODES PARTNERS Ltd purchased a new position in SiBone during the 4th quarter valued at about $29,000. Caitong International Asset Management Co. Ltd grew its stake in shares of SiBone by 64,700.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock valued at $38,000 after buying an additional 1,941 shares in the last quarter. State of Wyoming acquired a new stake in SiBone in the 2nd quarter worth approximately $55,000. Canada Pension Plan Investment Board acquired a new stake in SiBone in the 2nd quarter worth approximately $68,000. Finally, Larson Financial Group LLC lifted its holdings in SiBone by 42.3% in the 4th quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock worth $70,000 after purchasing an additional 1,061 shares during the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on SIBN shares. Wall Street Zen lowered SiBone from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. TD Cowen lowered their price objective on SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Finally, Truist Financial reiterated a “buy” rating and issued a $18.00 price target (down from $20.00) on shares of SiBone in a research report on Tuesday, May 12th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

SiBone Price Performance

SiBone stock opened at $15.42 on Monday. The business’s 50-day simple moving average is $13.94 and its 200 day simple moving average is $15.81. The stock has a market cap of $683.88 million, a price-to-earnings ratio of -39.54 and a beta of 0.70. SiBone has a 12-month low of $11.48 and a 12-month high of $21.89. The company has a quick ratio of 8.34, a current ratio of 9.99 and a debt-to-equity ratio of 0.20.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.07. The business had revenue of $52.59 million for the quarter, compared to analysts’ expectations of $51.16 million. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%. As a group, research analysts anticipate that SiBone will post -0.44 earnings per share for the current year.

Insider Transactions at SiBone

In other SiBone news, Director Jeffrey W. Dunn sold 3,575 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $15.25, for a total value of $54,518.75. Following the transaction, the director owned 16,057 shares of the company’s stock, valued at approximately $244,869.25. This represents a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Laura Francis sold 14,957 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $14.71, for a total value of $220,017.47. Following the completion of the transaction, the chief executive officer directly owned 503,444 shares in the company, valued at $7,405,661.24. The trade was a 2.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 36,327 shares of company stock valued at $520,834. Corporate insiders own 3.90% of the company’s stock.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.